RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the closing (the “Closing”) of the previously announced underwritten secondary offering of

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the

RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the “Selling Shareholder”), an affiliate of The Carlyle Group,

RARITAN, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming investor conferences:

 -- Ortho's new VITROS ®  Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection.  -- Ortho is the first company to have an EUA for both a quantitative IgG

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics RARITAN, N.J., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in-vitro diagnostics (IVD) companies, today

RARITAN, N.J. , July 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care

RARITAN, N.J., July 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4,

RARITAN, N.J. , July 22, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its VITROS ® Immunodiagnostic Products IL-6 Reagent Pack, the latest addition to Ortho's VITROS ® Critical Care menu, is

- Ortho's new VITROS ®  Anti-SARS-CoV-2 IgG Quantitative Test targets the S1 spike protein and is   calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measu re antibody response to SARS-CoV-2 - Ortho